<?xml version="1.0" encoding="UTF-8"?>
<p id="p0020">The potential adverse psychological impact of viral infection in patients with established psychiatric illnesses is uncertain: individuals with known mental health problems may be particularly vulnerable, but the effects of the pandemic on risk of relapse or need for increased use of mental health services in this group are not yet established.
 <xref rid="bib3" ref-type="bibr">
  <sup>3</sup>
 </xref>
 <sup>,</sup>
 <xref rid="bib4" ref-type="bibr">
  <sup>4</sup>
 </xref> However, many of the experimental approaches to treating COVID-19 infection – including azithromycin, hydroxychloroquine and remdesivir – have a risk of interaction with concomitantly prescribed psychotropic medication.
 <xref rid="bib5" ref-type="bibr">
  <sup>5</sup>
 </xref> Psychiatrists therefore need to be especially attentive to current patients, working to minimize relapse and prevent avoidable admissions to potentially hazardous hospital environments where physical distancing can be hard; and they should be aware of potential interactions with psychotropic medications if a patient develops severe COVID-19 infection. They also need to be assertive when protecting staff and environmental resources as these might be vulnerable to diversion to more obviously ‘front-line’ physical health services.
</p>
